Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS: During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, OM reduced incidence of the primary outcome over 22 months of follow-up (37.0% vs 39.1%; HR, 0.92 [95% CI 0.85-0.99]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationRegularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v039.i05 · Cited by 2,499
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationRepeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Cited by
Items 401–500 of 709
Ugariogu, S. N., Al‐Tannak, N. F., & Alenezi, S. S. (2025) · Kuwait Journal of Science · doi:10.1016/j.kjs.2025.100438 · Cited by 4
Sakata, K., Matsuyama, S., Kurebayashi, N., Hayamizu, K., Murayama, T., Nakamura, K., Kitamura, K., Morimoto, S., & Takeya, R. (2021) · Genes to Cells · doi:10.1111/gtc.12873 · Cited by 4
Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review
RabieeRad, M., Dabaghi, G. G., Zare, M. M., & Amani‐Beni, R. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101740 · Cited by 4
Chen, L., He, W., Gao, L., Lü, Y., & Zhu, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157549 · Cited by 4
Optimal Inotrope and Vasopressor Therapy in Cardiogenic Shock
Bae, D. (2025) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2024.0030 · Cited by 4
Guidetti, F., Lund, L. H., Benson, L., Hage, C., Lindberg, F., Basile, C., Villaschi, A., Musella, F., Stolfo, D., Scorza, R., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.03.008 · Cited by 4
Self-citationDrugs targeting the sarcomere in heart failure and hypertrophic cardiomyopathy
Lim, G. B. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00488-y · Cited by 4
Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure
Harrington, J., Sun, J., Fonarow, G. C., Heitner, S. B., Divanji, P., Allen, L. A., Alhanti, B., Yancy, C. W., Albert, N. M., DeVore, A. D., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.08.013 · Cited by 4
Self-citationZhang, L., Kulkarni, P., Farshidfar, F., Tingley, W. G., Hoey, T., Wang, W., Priest, J. R., & Figarska, S. M. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04753-1 · Cited by 3
Batho, C. A. P., Hudson, J. E., & Wilson, C. H. (2025) · Biochemical Society Transactions · doi:10.1042/bst20243001 · Cited by 3
Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study
Raccah, B. H., Biton, B., Amir, O., Gotsman, I., Nahman, D., & Matok, I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.769896 · Cited by 3
Towards etiological treatments in cardiomyopathies
Lairez, O., Fournier, P., Itier, R., Bachelet, B., Huart, A., & Cariou, E. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104223 · Cited by 3
Emerging Targeted Therapies for Inherited Cardiomyopathies and Arrhythmias
Ryan, T. L., & Roberts, J. D. (2023) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2023.04.006 · Cited by 3
Wang, M., Zuo, Z., Wu, T., & Zhou, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1644757 · Cited by 3
How to Change the Medical History of Patients with Heart Failure and Recurrent Hospitalizations?
Andrade, F. A., Monferdini, L., & Vieira, J. L. (2023) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20230092 · Cited by 3
Tsuji, S., Otani, C., Horie, T., Watanabe, S., Baba, O., Sowa, N., Ide, Y., Kashiwa, A., Makiyama, T., Imai, H., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115850 · Cited by 3
Piña, I. L., Gibson, G. T., Zieroth, S. R., & Kataria, R. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac112 · Cited by 3
Liu, Z., Zhang, Z., Zou, T., Fang, M., Wang, T., Meng, H., Chen, Y., Duan, Y., Wei, L., Han, J., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106206 · Cited by 3
Contemporary clinical role of echocardiography in patients with advanced heart failure
Nuzzi, V., Manca, P., Mulè, M., Leone, S., Fazzini, L., Cipriani, M., & Faletra, F. F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10434-6 · Cited by 3
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches
Dunlay, S. M., Colvin, M. M., Cowger, J. A., Leiro, M. G. C., Desai, A. S., Greene, S. J., Gustafsson, F., HALL, S., Ilonze, O. J., Lala, A., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103101 · Cited by 3
A multidisciplinary approach to heart failure care in the hospital: improving the patient journey
Rao, V. U., Bhasin, A., Vargas, J., & Kumar, V. A. (2022) · Hospital Practice · doi:10.1080/21548331.2022.2082776 · Cited by 3
Majoros, Z., Kiss, R. G., & Pál, T. (2022) · Cardiologia Hungarica · doi:10.26430/chungarica.2022.52.2.112 · Cited by 3
Métodos diagnósticos cardiovasculares en pacientes con diabetes mellitus. Revisión
Ramón-Ríos, A., Espejel-Guzman, A., Cabello‐Ganem, A., Serrano‐Roman, J., Aparicio-Ortiz, A. D., Fernández-Badillo, V., Palacios-Cruz, M., & Espinola-Zavaleta, N. G. (2023) · Gaceta Médica de México · doi:10.24875/gmm.m23000766 · Cited by 3
Emerging therapeutic directions for inotropic therapy in heart failure
Pironti, G., Maack, C., Andersson, D. C., & Lund, L. H. (2026) · Med · doi:10.1016/j.medj.2026.101073 · Cited by 3
de Oliveira, M. T., Barretto, A. C. P., Carlo, C. H. D., Jallad, S., & Chaud, M. S. D. A. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220009 · Cited by 3
Lindberg, F., Øigaard, N., Metra, M., Rosano, G. M. C., Dahlström, U., Mol, P. G. M., Hage, C., Lund, L. H., & Savarese, G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303348 · Cited by 3
Self-citationNew Progress of Positive Inotropic Drugs in the Treatment of Heart Failure
熊, 珂. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.127948 · Cited by 3
Belenichev, I. F., Popazova, O., Goncharov, O., Bukhtiyarova, N. V., Ryzhenko, V. P., Semenov, D., Oliynyk, S., Petakh, P., & Kamyshnyi, O. (2026) · Biomedicines · doi:10.3390/biomedicines14051018 · Cited by 3
Ganju, J. (2025) · Pharmaceutical Statistics · doi:10.1002/pst.70015 · Cited by 3
(2024) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2024.19.s1 · Cited by 3
Greenberg, L., Stump, W. T., Lin, Z., Bredemeyer, A. L., Blackwell, T. W., Han, X., Greenberg, A. E., Garcia, B. A., Lavine, K. J., & Greenberg, M. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.05.588306 · Cited by 3
Novel therapies in inherited cardiomyopathies
de Feria, A., & OWENS, A. T. (2021) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2021.101444 · Cited by 3
Trivedi, A., Sohn, W. Y., Jafarinasabian, P., Zhang, H., Terminello, B., Flach, S. D., Abbasi, S. A., Dutta, S., & Lee, E. W. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.997 · Cited by 3
Self-citationLongobardi, S., Sher, A., & Niederer, S. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-78710-3_39 · Cited by 3
Optimization-based methodologies for detection and monitoring of groundwater sources
Jin, X. (2008) · NCSU Libraries Repository (North Carolina State University Libraries) · Cited by 3
Year in Review 2021: Noteworthy Literature in Cardiothoracic Anesthesia
Smoroda, A., Douin, D. J., Morabito, J. E., Lyman, M., Prin, M., Ahlgren, B., Young, A., Christensen, E., Abrams, B. A., Weitzel, N. S., et al. (2022) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/10892532221100660 · Cited by 3
Singh, R. R., Slater, R. E., Wang, J., Wang, C., Guo, Q., Motani, A. S., Hartman, J. J., Sadayappan, S., & Ason, B. L. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.04.013 · Cited by 3
Classification of Heart Failure: A Farewell to Ejection Fraction?
Lüscher, T. F. (2020) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2020.70138 · Cited by 3
Kaźmierczak, K., Liang, J., Maura, L. G., Scott, N. K., & Szczesna‐Cordary, D. (2023) · Life · doi:10.3390/life13071463 · Cited by 3
Comparative Prognosis of Chagas and Other Cardiomyopathies
Ono, R., Docherty, K. F., Henderson, A. D., Echeverría, L. E., Felker, G. M., Lópes, R. D., Martinez, F., Packer, M., Ramires, F. J. A., Teerlink, et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.022 · Cited by 3
Self-citationHeart failure or heart success?
TERAMOTO, K., Tromp, J., & Lam, C. S. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab022 · Cited by 3
ATP directly modulates thick filament structure and function in porcine myocardium
Rhodehamel, M., Guo, M., Jani, V., Flannagan, H., Yuan, S., Landim-Vieira, M., & Ma, W. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.06.037 · Cited by 2
Reporting and Definition of Kidney Death in Heart Failure Clinical Trials
Khan, M. S., Shahid, I., & Butler, J. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101382 · Cited by 2
Habon, T., & Sepp, R. (2022) · Cardiologia Hungarica · doi:10.26430/chungarica.2022.52.2.122 · Cited by 2
Tanna, G. L. D., Angell, B. J., Urbich, M., Lindgren, P., Gaziano, T. A., Globe, G. A., & Stollenwerk, B. (2022) · PharmacoEconomics · doi:10.1007/s40273-022-01174-2 · Cited by 2
López-Guillén, J. L., Esmel-Vilomara, R., Rodoman, I., Constante, A. D., Kendall, I. S., Freixa‐Benavente, A., Diaz‐Gil, D., Cantarutti, N., Moscatelli, S., & Jeewa, A. (2025) · European Journal of Pediatrics · doi:10.1007/s00431-025-06263-w · Cited by 2
Alzate, J. A., Rajendran, P. S., & Gaggin, H. K. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010156 · Cited by 2
Nuevo árbol de decisión para el tratamiento de la insuficiencia cardíaca crónica de la redGDPS
Gil, F. M. A., Osoro, I. A., de la Puente, J. B., Cuenca, A. M. C., Franch‐Nadal, J., García, O. G., Franco, J. L. P., Quintero, M. R., & Muñoz, A. V. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.2.art3 · Cited by 2
Zhu, L., & Shi, P. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04059-9 · Cited by 2
Lo scompenso cardiaco a 360 gradi
Gnerre, G. E. P., & Pasquale, G. D. (2021) · Italian Journal of Medicine · doi:10.4081/itjm.q.2021.2 · Cited by 2
Asano, T., Maeno, Y., Nakano, M., Taguri, M., Miyasaka, M., Nakai, D., Miyazaki, I., Nasu, T., Tanimoto, S., Masuda, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102775 · Cited by 2
Polypill in heart failure: a pathway to simplified treatment and improved adherence and outcomes
Keramida, K., Savarese, G., Filippatos, G. S., & Yusuf, S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10559-2 · Cited by 2
Self-citationPalomas, J. L. B., de Polavieja, J. I. M. G., Pérez, M. P., Rangel‐Sousa, D., Fernández, A. C., Aguilera, J. L., Cortés, C. O., & Calvo, F. T. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2215985 · Cited by 2
Heart Failure Drug Development Over the Eras
Blumer, V. L., Januzzi, J. L., Lindenfeld, J., Solomon, S. D., Psotka, M. A., Carson, P. E., Bristow, M. R., Abraham, W. T., Gandotra, C., Saville, B. R., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.03.021 · Cited by 2
Self-citationHeart Failure with Reduced Ejection Fraction
Barkoudah, E., & Yancy, C. W. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.010 · Cited by 2
Stawiarski, K. M., & Ramakrishna, H. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.02.023 · Cited by 2
Marques, P. S., Sharma, A., & Ferreira, J. P. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.01.011 · Cited by 2
Cotter, G., & Davison, B. A. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.05.015 · Cited by 2
Recent Advances in Novel Modulators for Cardiac Myosin Disorders
Wang, H., Wang, M., Han, B. R., Chen, Q., & Zhang, Q. (2025) · Pharmaceutical Fronts · doi:10.1055/a-2646-1097 · Cited by 2
Butler, J., Siddiqi, T. J., Zannad, F. M., Ferreira, J. P., Fillipatos, G., Anker, S. D., & Packer, M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2854 · Cited by 2
Self-citationVericiguat: resultados del estudio VICTORIA
Sánchez, M. A., Colet, J. C., Manzano, L., Zamorano, J. L., & González‐Juanatey, J. R. (2022) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(22)00003-6 · Cited by 2
Forrai, Z., Schäffer, P. P., Gergely, T. G., Kazay, Á., Hanuska, L. F., Czurkó, K., Pilecky, D., Andreka, P. G., Piróth, Z., Bánfi‐Bacsárdi, F., et al. (2026) · Orvosi Hetilap · doi:10.1556/650.2026.33492 · Cited by 2
Foà, A., Vaduganathan, M., Claggett, B. L., Díaz, R., Malik, F. I., Heitner, S. B., Kupfer, S., Divanji, P., Felker, G. M., Metra, M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag023 · Cited by 2
Self-citationTrivedi, A., Malik, F. I., Mackowski, M., Hutton, S., Aoki, M., Abbasi, S. A., Dutta, S., & Lee, E. W. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00711-2 · Cited by 2
Self-citationResearch progress on pathogenic genes of dilated cardiomyopathy
Zhang, X., Zhang, X., Chen, Y., Huan, N., Wang, C., & Zhang, D. (2026) · iScience · doi:10.1016/j.isci.2026.115511 · Cited by 2
Kim, E., & Agrawal, D. K. (2026) · Archives of Internal Medicine Research · doi:10.26502/aimr.0254 · Cited by 2
Insuficiencia cardíaca con fracción de eyección ventricular izquierda reducida
Vega, J. D. S., Luque, M. C. A., Salinas, G. L. A., & Gómez, J. L. Z. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.06.002 · Cited by 2
THE HEART OF HUMANS AND DOMESTIC SWINE: A COMPARATIVE APPROACH - A LITERATURE REVIEW
Delgado, A. L. J., de Melo, L. F., Magalhães, H. I. R., da Silva, M. O., Miglino, M. A., & da Anunciação, A. R. D. A. (2023) · doi:10.22533/at.ed.6942309018 · Cited by 2
Alawajneh, M. M., Aljabali, A. S., Theeb, L. S., Tashtoush, S., Alshwayyat, S., Mostafa, A. B., Alhuneafat, L., Laudani, C., & Altibi, A. M. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133901 · Cited by 2
Herzinsuffizienz: Diagnostik und Therapie gemäß der ESC Leitlinie 2021
Herting, J., Fischer, T. H., & Maack, C. (2022) · Der Nephrologe · doi:10.1007/s11560-022-00575-w · Cited by 2
Emerging Mechanisms and Therapeutic Strategies in Dilated Cardiomyopathy
Wang, L., Chen, C., & Wang, D. W. (2026) · Biomedicines · doi:10.3390/biomedicines14030523 · Cited by 2
Dilated and hypokinetic non-dilated cardiomyopathy
Seferovic, P. M., Bozkurt, B., & Polovina, M. M. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0007 · Cited by 2
Restrictive Cardiomyopathy: A Comprehensive Literature Review
Fakih, Y., Sakan, M. M. A., Fawaz, N., Ghazawi, A. E., Fawaz, A., & Refaat, M. M. (2025) · Annals of Clinical Cardiology · doi:10.4103/accj.accj_2_25 · Cited by 2
Dynamics of the Pre-Powerstroke Myosin Lever Arm and the Effects of Omecamtiv Mecarbil
Childers, M. C., & Regnier, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910425 · Cited by 2
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction
Ono, R., Chimura, M., Docherty, K. F., Jhund, P. S., Yang, M., Henderson, A. D., Metra, M., Liu, G., Divanji, P., Heitner, S. B., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102900 · Cited by 2
Self-citationHe, H., Yang, J., Wu, Y., Lin, P., Lai, T., Jia, J., Li, J., & Lin, W. (2026) · Smart Molecules · doi:10.1002/smo2.70044 · Cited by 2
Self-citationSíndrome Cardio-Renal: Revisión Mecanística
Dumler, F. (2022) · Diagnóstico · doi:10.33734/diagnostico.v61i2.364 · Cited by 2
Stimulation of Contractility in Systolic Heart Failure
Swedberg, K. B. (2021) · New England Journal of Medicine · doi:10.1056/nejme2033311 · Cited by 2
Omecamtiv Mecarbil use in systolic heart failure- Results of the GALACTIC-HF trial
Shah, S. R., Ali, A., & Ikram, S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900727 · Cited by 2
Advances in understanding the state of titin truncation variants in dilated cardiomyopathy
Solaro, R. J. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02664-0 · Cited by 2
The Future for Inotropes in Heart Failure. Do Not Throw the Baby Out With the Bathwater!
Pollesello, P., & Papp, Z. L. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001377 · Cited by 2
Sarkar, S. S., Redd, M. A., Hartman, J. J., Hwee, D. T., Bat-Erdene, A., Kim, L. H., Chuang, C., Rupert, C. E., Abi‐Gerges, N., Rodriguez, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.23.701387 · Cited by 1
Self-citationZhang, X., & Zhang, H. (2023) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2023.100010 · Cited by 1
Genetic Determinants of Early Heart Failure in Hypoplastic Left Heart Syndrome
Balint, B., Sunthankar, S. D., Monaco, G., Bair, C. A., Wolfe-Miller, R., Gonzalez, C. D., Portillo, C. A., MacKenzie, D., Freedy, K., Onorato, A. C., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.031 · Cited by 1
Self-citationGan, H., Tang, H. Y., Huang, Y., Wang, D., Pu, P., & Zuo, Z. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203069 · Cited by 1
Gilyarevsky, S. R., & VIu, M. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5422 · Cited by 1
Omecamtiv Mecarbil as a Therapy for Heart Failure With Low Ejection Fraction
Drazner, M. H. (2022) · JAMA · doi:10.1001/jama.2022.6805 · Cited by 1
Understanding Heart Failure: Evolution of Concepts and Treatments
Šmalcelj, A. (2024) · Cardiologia Croatica · doi:10.15836/ccar2024.251 · Cited by 1
Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus
Gorb, Y. G., Serik, S. A., Tkachenko, O. V., & Ryabukha, V. V. (2022) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs07.01.014 · Cited by 1
Gándara-Ricardo, J. A., Muñoz-Ortiz, E., Aguilar-Molina, O. E., García-Rueda, K. A., Giraldo-Ramírez, S., Salamanca, J. F., & Sénior, J. M. (2021) · Acta Médica Colombiana · doi:10.36104/amc.2021.2108 · Cited by 1
Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
Birner, C. M., Laufs, U., & Frey, N. (2021) · Der Kardiologe · doi:10.1007/s12181-021-00446-z · Cited by 1
Identification of key genes for heart failure in dilated cardiomyopathy in different populations
Yu, Y., Xue, C., Ji, D., Sheng, W., Gao, X., Wu, X., & Wu, C. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1618390 · Cited by 1
Innovationen in der medikamentösen Therapie der Herzinsuffizienz
Abdin, A., & Böhm, M. (2021) · CardioVasc · doi:10.1007/s15027-021-3544-y · Cited by 1
Self-citationKobalava, Z. D., & Назаров, И. С. (2023) · Kardiologiia · doi:10.18087/cardio.2023.3.n2418 · Cited by 1
Therapie der Herzinsuffizienz mit reduzierter Pumpfunktion
Abdin, A., & Böhm, M. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2054-9636 · Cited by 1
Self-citationTelle, Å., Charwat, V., Charrez, B., Finsberg, H. N. T., Healy, K. E., & Wall, S. (2025) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.70034 · Cited by 1
Chronic heart failure: from pathogenesis to personalized therapy and digital technologies
Yurkovskiy, A. O., Ложкина, Н. Г., & Николаевич, А. С. (2025) · Ateroscleroz · doi:10.52727/2078-256x-2025-21-3-340-361 · Cited by 1
Race-Based Analyses in Heart Failure Clinical Trials
Hale, S., & Yancy, C. W. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.01.014 · Cited by 1
From Calcium Channels to New Therapeutics
McDonough, S. I. (2022) · Springer eBooks · doi:10.1007/978-3-031-08881-0_27 · Cited by 1
Therapie der Herzinsuffizienz mit reduzierter Auswurffraktion: Was ist neu in den Leitlinien 2021?
Maeder, M. T., Rickli, H., Brenner, R., Scheler, E., & Buser, M. (2022) · Praxis · doi:10.1024/1661-8157/a003876 · Cited by 1
Metadata
- Authors
- Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., Böhm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlström, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Macdonald, P., Mareev, V., Momomura, S.-I., O’Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., & Kurtz, C. E.
- Affiliations
- San Francisco VA Medical Center (US)
- From the Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco (J.R.T.), Amgen, Thousand Oaks (L.S., J.C.L., N.H., S.A.A., C.E.K.), and Cytokinetics, South San Francisco (F.I.M.) — all in California; Estudios Clínicos Latino América, Rosario, Argentina (R.D.); the Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute, Durham (G.M.F.), and the University of North...
- Brigham and Women's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- Linköping University (SE)
- University of Bern (CH)
- ORCID
- Teerlink, John R.
- Felker, G. Michael
- McMurray, John J.V.
- Metra, Marco
- Solomon, Scott D.
- Anand, Inder
- Böhm, Michael
- Bonderman, Diana
- Cleland, John G.F.
- Dahlström, Ulf
- Fang, James C.
- Filippatos, Gerasimos
- Fonseca, Cândida
- Goudev, Assen R.
- Howlett, Jonathan G.
- Lanfear, David E.
- Li, Jing
- Lund, Mayanna
- Macdonald, Peter
- Momomura, Shin-ichi
- O’Meara, Eileen
- Parkhomenko, Alexander
- Ponikowski, Piotr
- Sliwa, Karen
- Voors, Adriaan A.
- Zannad, Faiez
- Abbasi, Siddique A.
- Malik, Fady I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 105-116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098430919
- Cited by
- 656
- References
- 26
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 76 · 2023: 150 · 2022: 130 · 2021: 148
- FWCI
- 68.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- RUC (Universidade Da Coruña) (submittedVersion)
- Funders
- Amgen
- Cytokinetics Inc.
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- omecamtiv mecarbil, cardiac myosin activator, heart failure with reduced ejection fraction, cardiovascular outcomes, heart failure hospitalization, cardiovascular mortality, N-terminal pro-brain natriuretic peptide, cardiac troponin I, symptom burden, pharmacokinetic-guided dosing, ventricular arrhythmias
- MeSH terms
- Aged, Aged, 80 and over, Cardiotonic Agents, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Myocardial Contraction, Stroke Volume, Urea, Cardiac Myosins, Heart Failure, Systolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.